Sibylle Loibl Selected Research

Ado-Trastuzumab Emtansine

9/2022	Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE.
1/2020	Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer.
1/2020	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
1/2019	Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sibylle Loibl Research Topics

Disease

277	Breast Neoplasms (Breast Cancer) 02/2024 - 05/2002
129	Neoplasms (Cancer) 01/2024 - 05/2002
41	Triple Negative Breast Neoplasms 04/2024 - 06/2014
32	Pathologic Complete Response 11/2023 - 04/2010
15	Neoplasm Metastasis (Metastasis) 03/2022 - 01/2008
10	Neutropenia 11/2023 - 07/2010
10	Carcinoma (Carcinomatosis) 11/2017 - 05/2002
8	Fatigue 11/2023 - 01/2006
8	Brain Neoplasms (Brain Tumor) 01/2023 - 02/2009
8	Febrile Neutropenia 01/2021 - 04/2010
7	Diarrhea 06/2023 - 04/2010
6	Disease Progression 06/2023 - 07/2008
6	Infections 01/2020 - 11/2011
5	Noninfiltrating Intraductal Carcinoma (DCIS) 12/2023 - 04/2012
5	Leukopenia 01/2021 - 07/2015
5	Residual Neoplasm 01/2019 - 12/2006
4	Exanthema (Rash) 06/2023 - 02/2012
4	Hypertension (High Blood Pressure) 01/2020 - 01/2012
4	Ovarian Neoplasms (Ovarian Cancer) 01/2018 - 12/2006
3	Inflammatory Breast Neoplasms 01/2021 - 01/2010
3	Anemia 01/2021 - 01/2006
3	Amenorrhea 01/2021 - 06/2011
3	Vomiting 01/2021 - 01/2020
3	Nausea 01/2021 - 01/2020
3	Cardiotoxicity 12/2020 - 01/2008
3	Circulating Neoplastic Cells 01/2018 - 05/2010
3	Thrombocytopenia (Thrombopenia) 07/2015 - 07/2013

Drug/Important Bio-Agent (IBA)

71	Hormones (Hormone)IBA 12/2023 - 01/2006
46	Trastuzumab (Herceptin)FDA Link 01/2024 - 02/2009
36	taxaneIBA 10/2021 - 01/2008
35	Biomarkers (Surrogate Marker)IBA 01/2024 - 01/2008
33	AnthracyclinesIBA 01/2021 - 01/2008
32	human ERBB2 proteinIBA 02/2024 - 01/2009
30	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2023 - 01/2006
23	ErbB Receptors (EGF Receptor)IBA 11/2023 - 10/2002
22	Paclitaxel (Taxol)FDA LinkGeneric 01/2023 - 07/2008
21	Epirubicin (Ellence)FDA LinkGeneric 01/2023 - 11/2007
19	Estrogen ReceptorsIBA 02/2023 - 02/2007
18	Capecitabine (Xeloda)FDA Link 11/2023 - 04/2008
17	Phenobarbital (Luminal)FDA Link 01/2024 - 11/2010
17	Docetaxel (Taxotere)FDA Link 03/2023 - 01/2006
14	palbociclibIBA 11/2023 - 07/2015
14	Proteins (Proteins, Gene)FDA Link 10/2021 - 10/2002
13	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 07/2008
12	130-nm albumin-bound paclitaxelIBA 11/2023 - 07/2010
12	Fulvestrant (Faslodex)FDA Link 06/2023 - 03/2015
12	Bevacizumab (Avastin)FDA Link 01/2020 - 01/2011
10	Epidermal Growth Factor (EGF)IBA 12/2023 - 10/2002
10	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 01/2006
9	Lapatinib (GW572016)FDA Link 08/2019 - 01/2008
8	Messenger RNA (mRNA)IBA 01/2021 - 02/2013
7	pertuzumabIBA 01/2024 - 07/2015
7	Taxoids (Taxanes)IBA 02/2016 - 01/2008
6	Immunoconjugates (Immunoconjugate)IBA 02/2024 - 01/2019
6	sacituzumab govitecanIBA 10/2023 - 01/2021
6	Progesterone Receptors (Progesterone Receptor)IBA 02/2023 - 01/2009
5	Aromatase InhibitorsIBA 12/2023 - 01/2016
5	Cyclin-Dependent Kinase 4IBA 06/2023 - 01/2017
5	Tamoxifen FDA LinkGeneric 01/2023 - 08/2005
5	Immune Checkpoint InhibitorsIBA 01/2023 - 10/2016
5	Poly(ADP-ribose) Polymerase InhibitorsIBA 04/2022 - 06/2011
5	ParaffinIBA 07/2020 - 01/2010
5	Formaldehyde (Formol)FDA Link 07/2020 - 01/2010
5	Fluorouracil (Carac)FDA LinkGeneric 01/2020 - 08/2003
5	Gonadotropin-Releasing Hormone (GnRH)FDA Link 01/2018 - 08/2005
5	Goserelin (Zoladex)FDA Link 01/2017 - 08/2005
4	RNA (Ribonucleic Acid)IBA 01/2023 - 11/2021
4	tucatinibIBA 01/2023 - 06/2018
4	Ado-Trastuzumab EmtansineIBA 09/2022 - 01/2019
4	Vinorelbine (Navelbine)FDA LinkGeneric 08/2022 - 04/2008
4	Monoclonal AntibodiesIBA 06/2018 - 04/2003
4	Bendamustine Hydrochloride FDA Link 12/2011 - 01/2008
4	Nitric Oxide (Nitrogen Monoxide)FDA Link 07/2008 - 09/2002
3	durvalumabIBA 04/2024 - 01/2021
3	Cyclin-Dependent Kinases (cdk Proteins)IBA 12/2023 - 07/2015
3	Anastrozole (Arimidex)FDA LinkGeneric 12/2023 - 01/2016
3	Denosumab FDA Link 11/2023 - 01/2022
3	Ibandronic Acid (Boniva)FDA Link 11/2023 - 10/2011
3	neratinibIBA 01/2023 - 06/2018
3	Tyrosine Kinase InhibitorsIBA 01/2023 - 06/2018
3	eribulin FDA Link 08/2022 - 01/2019
3	liposomal doxorubicin (Doxil)FDA Link 01/2022 - 01/2019
3	Estrogens (Estrogen)FDA Link 01/2021 - 01/2006
3	Letrozole (Femara)FDA LinkGeneric 01/2021 - 03/2015
3	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 07/2020 - 10/2014
3	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 03/2016
3	Cytotoxins (Cytolysins)IBA 01/2019 - 01/2008
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2015 - 01/2011
3	Methotrexate (Mexate)FDA LinkGeneric 10/2015 - 11/2007
3	LipidsIBA 04/2014 - 05/2011
2	Surface Antigens (Surface Antigen)IBA 02/2024 - 01/2021

Therapy/Procedure

118	Neoadjuvant Therapy 02/2024 - 01/2006
106	Therapeutics 12/2023 - 10/2002
91	Drug Therapy (Chemotherapy) 02/2024 - 08/2005
16	Adjuvant Chemotherapy 01/2024 - 01/2008
6	Radiotherapy 02/2024 - 02/2009
6	Aftercare (After-Treatment) 06/2023 - 10/2011
5	Immunotherapy 04/2022 - 11/2017
4	Combination Drug Therapy (Combination Chemotherapy) 01/2021 - 01/2010
3	Lymph Node Excision (Lymph Node Dissection) 10/2023 - 10/2019